AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
New Chemotherapy Preparation Significantly Reduces Cardiotoxicity.(liposome-encapsulated doxorubicin less toxic for breast cancer treatment)
2001 MAR 29 - (NewsRx.com & NewsRx.net) -- A chemotherapy drug coated in tiny oil droplets is as effective as the standard preparation, but is much less toxic when used to treat women with advanced breast cancer.
The drug, doxorubicin, is one of the most effective chemotherapies for breast cancer available, but is known to cause damage to individual muscles and blood vessels of the heart (cardiotoxicity). The risk of heart failure can be as high as 5% in patients receiving the current maximum recommended dose. By surrounding doxorubicin in protective oils (liposomes), the drug can flow through the heart without dissolving, lowering the risk of heart damage, McGill University researchers have found.
In a Phase III clinical trial with 297 participants, investigators found that only 6% of patients with metastasized breast cancer developed cardiotoxicity when treated with liposome-encapsulated doxorubicin (known as Myocet), compared to 21% of women treated with standard doxorubicin. Both groups of patients also received the chemotherapy drug cyclophosphamide and both had equal response rates to treatment.
"Liposome-encapsulated doxorubicin passes right through the heart and lodges in organs such as the liver and in the blood vessels that feed tumors, and then slowly dissolves, allowing the doxorubicin to fight the cancer cells," said the study's lead author Gerald ...
- Center to conduct Phase II study of liposome encapsulated doxorubicin in breast...
- Newspaper article from: Cancer Weekly February 10, 1992 700+ words
...clinical trial of liposome-encapsulated doxorubicin (TLC D-99, Liposome...treat women with advanced breast cancer who have not had prior...including a model of breast cancer, TLC D-99 was shown...II studies in advanced breast cancer at other centers provide...
- NeoPharm Initiates Phase I Trials of Proprietary 'Liposome Encapsulated...
- Press release article from: PR Newswire October 21, 1997 700+ words
...proprietary "liposome encapsulated doxorubicin" (LED), the company...doxorubicin (non- liposome encapsulated doxorubicin) is frequently used...advantage of Liposome-Encapsulated Doxorubicin, which is being evaluated...prognostic marker for breast cancer. Statement Under ...
- NeoPharm Announces Positive Results of Phase I Clinical Trial with Liposome...
- Press release article from: PR Newswire June 9, 1998 700+ words
...positive results of its Phase I clinical trial with Liposome Encapsulated Doxorubicin ("LED"). LED demonstrated encouraging clinical activity...broxuridine) for use as a prognostic indicator for breast cancer. Statement Under the Private Securities Litigation Reform...
- Trial tests liposome-encapsulated doxorubicin in advanced prostate cancer.
- Newspaper article from: Health & Medicine Week June 7, 2004 700+ words
...net) -- Study finds that liposome-encapsulated doxorubicin (LED) is well tolerated in patients with...Oncology (Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent...
- Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency...
- Newspaper article from: AIDS Weekly November 1, 1993 700+ words
...9(8):741-746. AIDS-related Kaposi's sarcoma (KS) cells are highly sensitive to liposome-encapsulated doxorubicin (LED), a team of researchers reports. Current chemotherapy regimens for the treatment of KS have the drawback...
- Liposome encapsulated doxorubicin (TLC D-99) - pharmacokinetics in patients...
- Newspaper article from: Cancer Weekly Embree, L. Lohri, A. Gelmon, K. Mayer, L. Cullis, P. Pilkiewicz, F. Hudon, N. Heggie, J. Goldie, J. July 15, 1991 700+ words
AUTHORS: L. Embree, A. Lohri, K. Gelmon, L. Mayer, P. Cullis, F. Pilkiewicz, N. Hudon, J. Heggie and J. Goldie. British Columbia Cancer Agency, Vancouver. According to the authors' abstract of a poster presentation to the 27th annual meeting of the American Society of Clinical Oncology, held in
- Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency...
- Newspaper article from: Cancer Weekly Masood, R. Rahman, A. Husain, S.R. Salahuddin, S.Z. Gill, P. October 5, 1992 700+ words
AUTHORS: R. Masood, A. Rahman, S.R. Husain, S.Z. Salahuddin and P. Gill. Norris Cancer Center, University of Southern California, Los Angeles, California. According to the authors' abstract of a poster presentation to the 83rd annual meeting of the American Association for Cancer Research, held May
- New Formulation of Chemotherapy Drug (Evacet(TM)) for Metastatic Breast Cancer...
- Press release article from: PR Newswire May 17, 1999 700+ words
Liposome-Encapsulated Doxorubicin Shows Benefits Over...Formulation in Advanced Breast Cancer Patients ATLANTA...investigational liposome-encapsulated doxorubicin, in 297 women with metastatic breast cancer. Gastrointestinal...
- Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R)...
- Press release article from: PR Newswire February 5, 2009 700+ words
...overexpressing breast cancer patients. The median...advanced nonoperable breast cancer, while it exceeded...Myocet is a liposome-encapsulated doxorubicin-citrate complex...Myocet in women with breast cancer have shown that the...
- Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of...
- Press release article from: PR Newswire March 18, 2009 700+ words
...overexpressing breast cancer. Eligibility criteria...treatment of metastatic breast cancer," said Ronald H...Myocet is a liposome-encapsulated doxorubicin-citrate complex...Myocet in women with breast cancer have shown that the...
Source: HighBeam Research, New Chemotherapy Preparation Significantly Reduces...